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AObjective: Heparin coating of cardiopulmonary bypass circuits reduces the inflammatory response and increases
the thromboresistance during extracorporeal circulation. These properties enables a lower systemic heparin dose,
which has been shown to reduce the need for blood transfusions. Experience with this technique accumulated over
11 years has been analyzed.
Methods: All patients underwent on-pump coronary artery bypass grafting with heparin-coated circuits. Apart
from some patients receiving a high intraoperative dose of aprotinin, the systemic heparin dose was reduced,
with a lower level of an activated clotting time of 250 seconds during extracorporeal circulation. The overall strat-
egy aimed at a fast-track regimen, with early extubation, minimal use of blood transfusions, and rapid postoper-
ative recovery.
Results: Altogether, 5954 patients were included; 1131 (19.0%) were female (median age, 70 years), and 4823
were male (median age, 65 years). The median additive EuroSCORE was 3 (range, 0–14; mean 3.5  2.5). No
significant signs of clotting were seen in any part of the extracorporeal circuit. Bank blood products were given to
427 (7.2%) patients. Median extubation time was 1.7 hours. The stroke rate was 1.0%, transient neurologic def-
icits occurred in 0.7%, and perioperative myocardial infarction occurred in 1.2%. On the fifth day, 88.1% of the
patients were physically rehabilitated and ready for discharge. Thirty-day mortality was 0.9% (54 patients).
Conclusions: The experience with this patient cohort including mostly low- to medium-risk patients with a rela-
tively short cardiopulmonary bypass time indicates that coronary artery bypass grafting performed with heparin-
coated circuits and reduced level of systemic heparinization is safe and results in a very satisfactory clinical course.
No signs of clotting or other technical incidents were recorded. (J Thorac Cardiovasc Surg 2011;141:1145-9)Modern cardiac surgery has gained a high level of quality
over the years. Particularly for coronary artery bypass sur-
gery, the accumulated experience with a large number of
procedures performed every year has resulted in improved
results, despite the increasing number of elderly and high-
risk patients.1 The low mortality rate is likely due to a contin-
uous improvement in technical skill, simplified procedures,
improvements in myocardial protection, better anesthesia
and intensive care, and better techniques and equipment
for extracorporeal circulation. On this background, it might
be difficult, even impossible, to prove the effects of a single
step or a single procedure to be superior over those of an-
other. However, analyzing the experience obtained through
a substantial number of patients treated similarly over many
years might provide some information of clinical relevance.e Oslo Heart Center, Division of Cardiovascular and Respiratory Medicine and
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The Journal of Thoracic and CarHeparin-coated cardiopulmonary bypass (CPB) circuits
are known to reduce the inflammatory response during extra-
corporeal circulation.2-4 This modification of the artificial
surfaces in contact with blood is also shown to increase
thromboresistance, and the equipment enables a lower
systemic heparin dose, which might lead to reduced
bleeding and less blood transfusions.5-7 Encouraged by our
initial experience more than a decade ago,8,9 the use of
heparin-coated circuits and reduced systemic heparinization
became routine in our department for patients undergoing
first-time myocardial revascularization. The system was in-
tegrated in a fast-track regimen, aiming at rapid extubation
and physical rehabilitation, as well as minimal use of blood
transfusions. The objective of the present study was to eval-
uate the accumulated experience gained over a period of
11 years.MATERIALS AND METHODS
Patients’ Characteristics
From January 1, 1998, until December 2008, 6478 consecutive patients
underwent myocardial revascularization with heparin-coated CPB circuits
in our department. Patients who had undergone previous cardiac surgery
(n ¼ 98) and patients receiving a high intraoperative dose of aprotinin
(n¼ 426) were given a full dose of heparin and were excluded from the pres-
ent study. This left 5954 patients available for the analysis. Approximatelydiovascular Surgery c Volume 141, Number 5 1145
TABLE 1. Demographic data of 5954 patients undergoing consecutive
coronary artery bypass
Clinical variable Median (range)
Male patients (n ¼ 4823), age (y) 65 (31–89)
Female patients (n ¼ 1131 [19.5%]), age (y) 70 (27–89)
NYHA class III–IV (% of patients) 56.5
Urgent/emergency operation (% of patients) 19.2
Diabetes mellitus (% of patients) 17.2
Left main stenosis (% of patients) 27.8
Preoperative myocardial infarction (% of patients) 48.2
Ejection fraction 0.66 (0.15–0.95)
Ejection fraction<0.50 (% of patients) 17.0
EuroSCORE 3 (0–14)
NYHA, New York Heart Association.
Abbreviations and Acronyms
ACT ¼ activated clotting time
CABG ¼ coronary artery bypass grafting
CPB ¼ cardiopulmonary bypass
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D80% of the patients had elective operations. Some patient categories were
taken care of by a neighboring university department, such as patients
with severe renal dysfunction, patients in need of a combined carotid and
coronary operation, and those requiring operations for left ventricular aneu-
rysm. The subjects are consequently somewhat selected, which should be
taken into consideration when evaluating the results. Otherwise, a typical
coronary artery bypass patient population was treated (Table 1).Anesthesia
The anesthesia protocol was designed to permit early extubation and in-
cluded a combination of diazepam (0–0.2 mg/kg), midazolam hydrochlo-
ride (0–0.2 mg/kg), low-dose fentanyl (4–8 mg/kg), and pancuronium
bromide supplemented with isoflurane. An arterial and 2 central venous
lines were the standard. Extended monitoring with pulmonary catheters or
transesophageal echocardiography was rarely done and was restricted to
cases of postoperative cardiopulmonary decompensation. If not particularly
indicated, no chest radiographs were taken the day of the operation.Operation and CPB
Standard operative procedures included median sternotomy and CPB
with a 2-stage cannula in the right atrium and a cannula in the ascending
aorta. The aorta was crossclamped while the distal anastomoses were com-
pleted. Myocardial protection consisted of intermittent antegrade adminis-
tration of cold blood cardioplegic solution or crystalloid cardioplegic
solution (St. Thomas’ Hospital solution no. 2). Anastomosis between the
in situ left internal thoracic artery and the left anterior descending artery,
supplemented with saphenous vein grafts, was performed most often. The
proximal vein anastomoses were constructed during partial occlusion of
the ascending aorta while the patient was being rewarmed.
CPB was performed with either a Sto¨ckert roller pump (PFC III; Sto¨ckert
Instrumente GmbH, Munich, Germany) or a Maquet HL 30 roller pump
(Maquet Cardiopulmonary AG, Hirrlingen, Germany) with a pulsatile
flow control and at a flow rate of 2.4 L$m2$min1. Standard adult sizes
of the circuits were used and primed with 2000 mL of Ringer’s acetate.
Mild hypothermia (blood temperature, 32C–34C) was instituted immedi-
ately after the start of bypass. During the first years of the study period, 2
heparin-coated systems were used: the Carmeda Bio-Active Surface (Med-
tronic, Inc, Minneapolis, Minn) system and the Duraflo II equipment
(Baxter Healthcare Corp, Bentley Laboratories Division, Irvine, Calif). Be-
cause of changes in the manufacturer’s situation, only the Carmeda system
has been used since 2003 (73% of all patients).
A reduced dose of heparin (Nyco Pharma, Oslo, Norway), 150 IU/kg,
was administered for systemic anticoagulation. The activated clotting
time (ACT; HemoTec, Englewood, Colo) had to exceed 250 seconds before
CPB was started, and supplemental doses were administered, if necessary,
to maintain this target ACT. ACT was repeatedly determined during CPB,
after protamine administration, and 2 hours postoperatively. For neutraliza-
tion of heparin, a bolus dose of protamine (protamine sulfate; Novo Nor-
disk, Baksvard, Denmark), 1.3 mg/100 IU heparin, was administered. The
cannulas were removed before reversal of anticoagulation. Each circuit
was examined visually for evidence of clots or fibrin formation after the op-
eration. An additional protamine dose was considered if postoperative
bleeding was greater than 1.5 to 2 mL/kg body weight during the first 2 post-
operative hours.1146 The Journal of Thoracic and Cardiovascular SurBlood Salvage
The blood conservation protocol of the institution, previously described
in detail,10 was applied to all patients. The main steps included removal of
autologous blood before bypass for retransfusion after bypass (if the pa-
tient’s preoperative hemoglobin concentration was adequate, usually
>120 g/L), routine use of cardiotomy suction, intraoperative and postoper-
ative retransfusion of the oxygenator and circuit contents (without cell pro-
cessing), and postoperative autotransfusion of shed mediastinal blood up to
18 hours postoperatively. The amount of postoperative bleeding from the
time of sternal closure until the drains were removed was recorded. Normo-
volemic anemia was accepted to a hematocrit level of 0.25 postoperatively;
a level less than this was considered an indication for allogeneic red blood
cell transfusion.
RESULTS
Patients
Demographic data are listed in Table 1. The female pro-
portion was 19.0%. Most patients were in New York Heart
Association class III, and 11.1% of patients were in New
York Heart Association class IV. The number of urgent or
emergency operations was 1140 (19.2%). The median addi-
tive EuroSCORE was 3 (range, 0–14; mean, 3.5  2.5).
Operation and CPB
The ACT before starting bypass was a median of 289 sec-
onds (range, 225–900 seconds), and after 10, 30, and 50
minutes, the median ACT was 298 seconds (range, 179–
925 seconds), 281 seconds (range, 166–741 seconds), and
276 seconds (range, 182–740 seconds), respectively. The
patients received a median of 4 (range, 1–9; mean 4.3 
1.2) distal anastomoses. At least 1 internal thoracic artery
anastomosis was constructed in nearly all patients
(99.7%). The median aortic crossclamp time was 33 min-
utes (range, 6–105 minutes), and pump time was 53 minutes
(range, 11–165 minutes). There were no technical complica-
tions related to CPB, and no grossly visible clots were ob-
served in the circuits.
Postoperative Course
The patients were weaned from the ventilator a median of
1.7 hours (range, 0–700 hours) postoperatively (Table 2).gery c May 2011
TABLE 2. Postoperative course in 5954 patients undergoing coronary
artery bypass
Variable No. (%)
Ventilatory support postoperatively (h), median (range) 1.7 (0–700)
New episodes of atrial fibrillation (no. of patients) 1688 (30.1)
Postoperative myocardial infarction 71 (1.2)
Intra-aortic balloon pump 11 (0.2)
Stroke 58 (1.0)
Transient neurologic disturbances 41 (0.7)
Mediastinitis 38 (0.6)
30-d Mortality 54 (0.9)
TABLE 3. Blood conservation in 5954 patients undergoing coronary
artery bypass
Variable Median (range)
Prebypass autologous removal (mL), n ¼ 4865 1040 (100–3100)
Mediastinal drainage (mL) 640 (120–7355)
Postoperative autotransfusion (mL), n ¼ 5927 600 (120–3735)
Resternotomy for bleeding (patients) 126 (2.1%)
Patients receiving blood products (1 component) 425 (7.2%)
Red blood cells 362
Fresh frozen plasma 130
Platelets 82
Platelets preoperatively (3 103) 231 (68–999)
Platelets at discharge (3 103) 238 (28–873)
Hemoglobin concentration preoperatively (g/L) 144 (83–197)
Hemoglobin concentration at discharge (g/L) 118 (75–165)
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DWithin 5 hours, 98.8% of the patients were extubated. One
hundred twenty-six (2.1%) patients underwent re-
exploration for postoperative bleeding. The threshold for
re-exploration was low (mediastinal drainage>250 mL/h
for 2 hours) to avoid transfusions of allogeneic blood prod-
ucts. Eleven (0.2%) patients were assisted by an intra-aortic
balloon pump postoperatively. Seventy-five (1.3%) patients
received inotropic drug therapy for more than 30 minutes af-
ter the operation. Episodes of atrial fibrillation in patients
with preoperative sinus rhythm were encountered in
30.1%. Considering the low systemic heparinization, there
were no clinical indications of increased risk for thrombo-
embolic complications. The incidences of both neurologic
events and perioperative myocardial infarction were low
(Table 2). The diagnosis of stroke or transient neurologic
disturbances was done by a consultant neurologist. In most
cases a computed tomographic scan was performed, and
the diagnosis was prospectively stored in the database. On
the fifth postoperative day, 88.1% of the patients were
able to walk stairs or ambulate outside the hospital. The
30- day mortality was 0.9% (54 patients).Blood Salvage
More than 80% of the patients had a preoperative hemo-
globin concentration high enough to allow prebypass autol-
ogous blood removal (Table 3). The blood was returned to
the patients after termination of CPB. Most of the mediasti-
nal shed blood was autotransfused until the morning after the
operation. Altogether, 425 (7.2%) patients were given
banked blood or blood products, leaving 5529 (92.8%) pa-
tients to be discharged from the hospital without being ex-
posed to allogeneic blood products. The decrease in
hemoglobin concentration after the operation was 26 g/L
(Table 3).DISCUSSION
The present data indicate that the routine use of heparin-
coated CPB circuits combined with reduced systemic hepa-
rinization is safe and has encouraging clinical results, with
low rates of morbidity and mortality. The requirement for
banked blood transfusions was modest. No clotting forma-The Journal of Thoracic and Cartions or other technical problems were encountered, and
the incidences of thromboembolic events were within ex-
pected ranges for this patient group.
To our knowledge, this is by far the largest consecutive
series of patients undergoing coronary artery bypass grafting
(CABG) with heparin-coated CPB equipment. The experi-
ence accumulated over more than a decade might provide
relevant clinical information, although no evidence of being
superior to other treatment modalities can be demonstrated.
Ranucci and colleagues11 recently performed a meta-
analysis of 4360 patients retrieved from 36 controlled
randomized series, comparing biocompatible circuits with
uncoated controls. Only 6 series had more than 100 patients
in each arm. Patients treated with biocompatible circuits had
a lower rate of red cell transfusions and atrial fibrillation and
shorter durations of stay in the intensive care unit. The
blood-saving effect of reducing systemic anticoagulation
could not be evaluated from this analysis, but other clinical
reports have indicated less postoperative bleeding and
reduced banked blood requirements when decreasing
the amount of systemic heparin.5,6 In a prospective
randomized series of 203 patients undergoing CABG, the
total amount of mediastinal drainage was significantly less
in the patients undergoing CPB with heparin-coated circuits
and a low heparin dose compared with those patients treated
with uncoated but otherwise identical circuits and full sys-
temic anticoagulation.7
Concern has been raised regarding increased thromboge-
nicity when the level of systemic heparinization is reduced
during CPB with heparin-coated circuits.12 In previous
randomized studies we were not able to demonstrate any ev-
idence of increased thrombin formation, fibrinolytic activity,
or consumption of coagulation factors.7,13 These studies
were performed under similar clinical conditions as in the
present material, with low- to medium-risk patients undergo-
ing CABG and a relatively short CPB time. The clinical cor-
relate of modest postoperative bleeding indicates adequate
anticoagulation and the absence of hyperfibrinolysis. Similardiovascular Surgery c Volume 141, Number 5 1147
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times, with no indications of increased thrombogenicity.14
Heparin-coated circuits attenuate the inflammatory re-
sponse to CPB and have been shown to preserve organ func-
tion during and after surgical intervention.2-4 In a large
multicenter study of patients at higher risk,15 heparin-
coated circuits were associated with a shorter intensive
care unit and postoperative hospital stay and had a protective
effect on lung and kidney function. Other studies have indi-
cated that heparinized circuits reduce the cognitive dysfunc-
tion after CPB.16 These findings of improved organ function
might have had an effect on the rapid and uneventful postop-
erative recovery seen in most of our patients. Also, the pos-
itive influence on postoperative hemostasis might improve
the clinical course. As an integrated part of our blood conser-
vation protocol, the use of heparin-coated circuits and low
systemic anticoagulation resulted in a transfusion rate of
less than 8%. Transfusion of allogeneic blood and blood
products is known to carry several complications,17 and
we assume that the absence of transfusion-related morbidity
also was an important factor for the uneventful rehabilitation
after the operation.
Early tracheal extubation is another important step to ini-
tiate a fast postoperative recovery and might reduce the need
for conventional intensive care to a small number of pa-
tients.18 Early extubation improves postextubation intrapul-
monary shunt fraction19 and can prevent oversedation and
resultant depression of the respiratory center, which pro-
longs intensive care unit stay.
From a technical point of view, there were no events or
problems related to the low systemic heparinization in the
present series. However, in a previous study we experienced
some clots in the cardiotomy reservoir after CPB in 2 redo
patients.8 No detectable side effects were seen, but after
that time, we used a full heparin dose in this subgroup of pa-
tients. A minor portion of the patients receiving a high intra-
operative dose of aprotinin were also given a full dose of
heparin because of studies indicating increased thrombin
formation in combination with reduced anticoagulation.20
Other authors21 have also recommended a full heparin
dose in valve operations, and therefore reduced hepariniza-
tion should be restricted to first-time CABG.
The use of heparin-coated circuits is certainly not the ma-
jor reason for the good clinical results but is an important part
of a philosophy to reduce the deleterious effects of CPB and
to minimize blood transfusions. The ultimate approach
would be to perform coronary surgery without a heart–
lung machine. However, we have chosen to do the revascu-
larization on pump in all patients, taking advantage of per-
forming an optimal number of anastomoses on an arrested
heart. A recent multicenter report22 confirmed previous stud-
ies that off-pump CABG resulted in fewer grafts, and after 1
year, the patients had worse outcomes and a poorer patency
rate than the on-pump patients. In the present series the mean1148 The Journal of Thoracic and Cardiovascular Surnumber of distal anastomoses was 4.3, ranging from 1 to 9,
indicating a high rate of complete revascularization.
In this context other technical aspects should also be in fo-
cus, such as duration of CPB and ischemic arrest. Activation
of blood cells and the coagulation, fibrinolytic, and comple-
ment systems increase with time on bypass.13 It has also
been demonstrated that CPB time is a determinant for pro-
longed mechanical ventilation after CABG.23 With regard
to the ischemic stress imposed on the myocardium, studies
have shown that the duration of ischemic time is an indepen-
dent risk factor for the development of postoperative myo-
cardial infarction, starting relatively early after aortic
crossclamping.24 Therefore efforts should be made to plan
surgical procedures in a way that reduces the ischemic and
pump times to a minimum. However, this approach should
not compromise the aim of complete revascularization,
which is known to have a significant effect on long-term
morbidity and survival.25
In summary, the evaluation of this large patient cohort in-
cluding mostly low- to medium-risk patients with a relatively
short CPB time indicates that CABG performed with
heparin-coated circuits and reduced level of systemic hepa-
rinization is safe and results in a very satisfactory clinical
course. There were few postoperative complications, limited
need for banked blood transfusions, and short periods of
postoperative ventilatory support. The mortality was low,
and the patients were physically rehabilitated after a few
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